Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 yea...
Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body weights <30 kg) with congenital heart disease who had undergone the Fontan procedure. In the absence of clin...
Alternative Titles
Full title
Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_84f2ca20cce34d809d5416226dfd0fe3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_84f2ca20cce34d809d5416226dfd0fe3
Other Identifiers
ISSN
2163-8306
E-ISSN
2163-8306
DOI
10.1002/psp4.12830
